Navigation Links
Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
Date:7/7/2008

t few weeks and in HCV patients early in the fourth quarter of 2008.

About ANA773 and TLR Pharmacology

ANA773 is an orally administered prodrug of a novel TLR7-specific agonist. Results from pre-clinical pharmacology studies have shown that ANA773 can elicit desired immune responses and that the profile of response can be modulated by both dose and schedule of administration. Results of recently completed 13-week GLP toxicology studies have shown that with every-other-day dosing of ANA773, immune stimulation of a magnitude believed to confer therapeutic potential can be achieved without adverse toxicology findings. The immune stimulation observed with every-other-day dosing of ANA773 in monkeys included induction of interferon-alpha and interferon dependent responses at levels that are sustained over 13 weeks of dosing.

The recently obtained results with every-other-day dosing of ANA773 over 13 weeks contrast with results from prior 13-week animal toxicology studies that utilized daily dosing of ANA975, a TLR7 agonist prodrug previously in development by the Company for the treatment of chronic hepatitis C. In initial 13-week animal toxicology studies of ANA975 dosed daily, unexpected findings associated with intense immune stimulation were observed. When lower daily doses of ANA975 were then explored in a subsequent 13-week animal toxicology study, it was determined that adverse findings were present even at dose levels where desired immunostimulatory effects were not measurable, following which the decision was made in 2007 to discontinue development of ANA975.

Webcast of Conference Call

Anadys will host a conference call today, July 7, 2008 at 2:00 p.m. Pacific Daylight Time to discuss Anadys' plans to resume clinical investigation of the TLR7 mechanism in HCV. A live webcast of the call will be available online at http://www.anadyspharma.com. A telephone replay will also b
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
2. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
3. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
6. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
7. Isis Pharmaceuticals Conference Call Notice
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
9. XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
10. MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
11. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... DIEGO , Oct. 20, 2014  ResMed ... availability of the ResMed Data Exchange program, a ... home medical equipment (HME) and other health care ... timely, secure access to critical patient information. It ... ResMed,s AirView™ and U-Sleep™ patient management platforms with ...
(Date:10/20/2014)... 20, 2014  AnaptysBio, Inc., a leader in ... announced the appointment of Marco Londei , ... lead the preclinical and clinical development of AnaptysBio,s ... pleased to welcome Dr. Londei to AnaptysBio,s executive ... and Chief Executive Officer of AnaptysBio. "Dr. Londei,s ...
(Date:10/20/2014)... Pharmaceutic Labs announces the opening of its ... NY for admixing, compounding, drug shortages and ... the FDA standards for safety and quality, using 21 ... The 10,000 square foot outsourcing facility was ... and quality control. The company will produce sterile and ...
Breaking Medicine Technology:ResMed Launches ResMed Data Exchange 2AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2
... Reduced By an Average of More Than ... N.C., April 02, 2007 /PRNewswire/ --,Adding the ... 24-Hour(TM) Extended-Release Tablets to,Parkinson's patients' existing levodopa ... to continue,their daily activities for a longer ...
... MUNICH, Germany, April 03, 2007 /PRNewswire/ -- ... showing the,improved potency of oritavancin to stop ... common wetting agent (polysorbate 80) and one,study ... in a mouse model of pneumonia. Oritavancin, ...
Cached Medicine Technology:Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 2Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 3Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 4Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 5Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 2Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 3Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 4Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 5Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 6
(Date:10/20/2014)... Diego, CA (PRWEB) October 20, 2014 AttorneyOne.com, ... all the latest information from the FDA on Sit ... on October 10 not to purchase or use Sit and ... Sit and Slim II is promoted as weight loss product ... Sibutramine, removed from the market in 2010 for safety reasons, ...
(Date:10/20/2014)... Succeed is proud to announce that they ... in the Every Body Walk! campaign by Kaiser ... that encourages workers to be more active outside of the ... concluded at the end of September, was a friendly competition ... areas. Participating companies gave their staff pedometers and each ...
(Date:10/20/2014)... Viejo, California (PRWEB) October 20, 2014 Final ... announced the release of the Citrus theme for FCPX ... I would use to describe the Citrus theme” Says Christina ... so easy to look so professional.” , Citrus comes with ... Included with the template are: four transitions for added style, ...
(Date:10/20/2014)... Punzoné , the first line of ultra-premium ... lot to celebrate this month. October marks Italian Heritage Month ... contributions of Americans of Italian heritage and Italians in America. ... shares its favorite Italian cocktails and encourages everyone to enjoy ... if it is only in a glass. , Punzoné ...
(Date:10/19/2014)... October 20, 2014 Hastings and Hastings, ... years of service throughout the greater Phoenix area and ... representation with regard to catastrophic automobile accidents. Statistics have ... country and throughout Arizona. As such, Hastings and Hastings ... legal representation for those who have been injured through ...
Breaking Medicine News(10 mins):Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3
... treatment vs. watchful waiting , MONDAY, July 27 (HealthDay ... who have prostate cancer surgery but leaves unanswered the complicated ... treatment or just watchful waiting. , The study of almost ... removal of a cancerous prostate gland -- between 1987 and ...
... , , WASHINGTON, ... the National Press Club. National Press Club events are open to ... and Newsmakers. Events listed are subject to last-minute changes. Space may ... time and avoid waiting in line, tickets can be paid for ...
... (LRF) is pleased to announce that the 2009 Millennium ... has been awarded to Kai Fu, MD, PhD, Associate ... , Lymphoma, the most common type of ... and non-Hodgkin lymphoma (NHL). According to a 2008 ...
... in never-smokers is poorly understood, but a study led by ... at the National Cancer Institute has identified a molecule believed ... , The findings, published online recently in the Proceedings ... improved therapy for lung cancer in both never-smokers and smokers, ...
... , , PITTSBURGH, July 27 Childhood ... young adults and can lead to premature death in adulthood ... hypertension. In addition to its significant human toll, childhood obesity ... annually. , , To address the continued ...
... A ... the American Society of Andrology,s annual meeting. Study results showed marked improvement in sperm ... the ejaculate. , ... Bellingham, WA (PRWEB) July 23, 2009 -- A clinical study for the male fertility ...
Cached Medicine News:Health News:Men Who Have Prostate Cancer Surgery Do Well 2Health News:Men Who Have Prostate Cancer Surgery Do Well 3Health News:Millennium Pharmaceuticals Inc./Lymphoma Research Foundation funds lymphoma research 2Health News:Molecule plays early role in nonsmoking lung cancer 2Health News:Highmark Provides Pediatricians With Resources to Combat Childhood Obesity 2Health News:Highmark Provides Pediatricians With Resources to Combat Childhood Obesity 3Health News:Male Fertility Supplement Improves Sperm Quality & Motility in Clinical Study 2Health News:Male Fertility Supplement Improves Sperm Quality & Motility in Clinical Study 3Health News:Male Fertility Supplement Improves Sperm Quality & Motility in Clinical Study 4
Sharp tipped straight scissors. For cutting in the iris plane or cutting peripheral membranes. May also be useful in ROP cases....
Microscissors : Horizontal Scissors...
Low profile, sharp-tipped scissors with a vertical cutting action. Excellent for peeling and cutting fine epiretinal membranes....
... with a curvature of 12 ... of the retina. Instrument shaft ... For cutting membranes adherent to ... for cutting in small folds ...
Medicine Products: